Investors have gained Rs 3,93,349.08 crore in four days following a strong rally in the equity markets amid a declining trend in COVID-19 cases. In four consecutive sessions of gains, the 30-share BSE Sensex has climbed 1,299.91 points or 2.56 per cent.
The BSE benchmark index on Monday closed at 51,937.44, a gain of 514.56 points or 1 per cent. In four days, the market capitalisation of BSE-listed companies zoomed Rs 3,93,349.08 crore to close at a record high of Rs 2,22,99,810.27 crore on Monday.
"After making a flat start, market extended gains throughout the session. Investor sentiments remained bullish over hopes of revival in the global economy and a declining trend in COVID-19 cases continues to offer comfort to investors. "Index heavyweight Reliance and large banking stocks like ICICI Bank and HDFC Bank were among the top contributors to benchmark gains in today's session," said Sumeet Bagadia, Executive Director, Choice Broking.
Reliance Industries was the biggest gainer in the 30-share frontline companies pack, jumping 3.13 per cent, followed by ICICI Bank, Bharti Airtel, Dr Reddy's, Maruti and ITC. In contrast, M&M, Infosys, L&T and IndusInd Bank were among the laggards.
Frequently Asked Questions
A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.
There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.
Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.